Comparable stake leader
Flagship Pioneering Fund VII General Partner LLC
SEC ownership of Evelo Biosciences, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001694665.
Disclosed value leader
Flagship Pioneering Fund VII General Partner LLC
Comparable rows
0/25
Latest evidence
07 Nov 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Flagship Pioneering Fund VII General Partner LLC
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
07 Nov 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001694665
- Issuer location
- Foxboro, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Evelo Biosciences, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Flagship Pioneering Fund ...
Disclosed value leader
Flagship Pioneering Fund ...
Comparable rows
0/25
Latest evidence
07 Nov 2023
3/4/5
Highest disclosed value: $4,520,548
25 rows are not safely comparable across share classes.
Showing 1-8 of 25 holder rows.
Quick read
Flagship Pioneering Fund VII General Partner LLC has the largest disclosed position value at $4.52M.
0 of 25 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Flagship Pioneering Fund VII General Partner LLC's linked filing trail.
Disclosed position value
Top 5
Flagship Pioneering Fund VII Gene...
$4.52M
Flagship Ventures Fund IV General...
$2.62M
Horizon Technology Finance Corp
$714.3K
David R. Epstein
$31K
Mark Bodmer
$8.5K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 25 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Flagship Pioneering Fund VII General Partner LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$4,520,548
13,698,630 shares
|
— | 27 May 2022 |
| Flagship Ventures Fund IV General Partner LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$2,617,765
7,932,624 shares
|
— | 11 Jul 2023 |
| Horizon Technology Finance Corp |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$714,286
2,164,502 shares
|
— | 11 Jul 2023 |
| David R. Epstein |
3/4/5
Director
|
—
class O/S missing
|
$30,998
93,932 shares
|
— | 30 Jun 2022 |
| Mark Bodmer |
3/4/5
CSO, President of R&D
|
—
mixed-class rows
|
$8,492
32,357 shares
mixed-class rows
|
— | 07 Nov 2023 |
| Marella Thorell |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
$7,345
28,759 shares
mixed-class rows
|
— | 07 Nov 2023 |
| Simba Gill |
3/4/5
President & CEO, Director
|
—
mixed-class rows
|
$5,860
32,994 shares
mixed-class rows
|
— | 07 Nov 2023 |
| Duncan McHale |
3/4/5
Chief Medical Officer
|
—
mixed-class rows
|
$5,605
23,484 shares
mixed-class rows
|
— | 07 Nov 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 26 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 25 reporting-owner rows connected to Evelo Biosciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
25
Largest Forms 3/4/5 holder
Flagship Pioneering Fund VII General Partner LLC
Net 12M change
$0
Latest report
07 Nov 2023
Recent insider transactions for Evelo Biosciences, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.